THALLOUS CHLORIDE TI-201 INJECTION SOLUTION

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

THALLIUM CHLORIDE(TI 201)

זמין מ:

CURIUM CANADA INC

קוד ATC:

V09GX01

INN (שם בינלאומי):

THALLIUM 201 TL CHLORIDE

כמות:

37MBq

טופס פרצבטיות:

SOLUTION

הרכב:

THALLIUM CHLORIDE(TI 201) 37MBq

מסלול נתינה (של תרופות):

INTRAVENOUS

יחידות באריזה:

10ML

סוג מרשם:

Schedule C

איזור תרפויטי:

ROENTGENOGRAPHY

leaflet_short:

Active ingredient group (AIG) number: 0152598004; AHFS:

מצב אישור:

APPROVED

תאריך אישור:

2018-12-07

מאפייני מוצר

_Page 1 of 21 _
PRODUCT MONOGRAPH
THALLOUS CHLORIDE TL 201 INJECTION
Thallium Tl 201
Solution for intravenous use containing per mL, 37 megabecquerels (1
millicurie)
Thallous Chloride Tl 201 at calibration time.
Radiodiagnostic Agent
Curium Canada Inc.
2572 boul. Daniel-Johnson, Suite 245-249
Laval, QC, H7T-2R3
CANADA
Date of Revision: April 26
th
, 2019
CONTROL NUMBER: 225111
_Page 2 of 21 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
DESCRIPTION...................................................................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
5
CONTRAINDICATIONS
..................................................................................................
6
WARNINGS AND PRECAUTIONS
.................................................................................
6
ADVERSE REACTIONS
...................................................................................................
9
DRUG INTERACTIONS
...................................................................................................
9
DOSAGE AND ADMINISTRATION
.............................................................................
10
RADIATION DOSIMETRY
............................................................................................
12
OVERDOSAGE
...............................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 13
STORAGE AND STABILITY
.........................................................................................
14
SPECIAL HANDLING INSTRUCTIONS
......................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................